Innophore supports strain optimization through structure-based enzyme engineering for microbial production systems. The approach focuses on improving pathway-relevant redox and hydrolytic enzymes to increase product formation, enhance process stability, and reduce undesired side products.
The methodology combines Innophore’s Catalophore™ technology with evolutionary conservation analysis, rational mutagenesis, computational protein design, ancestral sequence reconstruction, and deep learning-guided predictions. These methods enable the prioritisation of enzyme variants that support efficient and selective biosynthetic pathways.
The workflow supports strain optimization by improving enzymes within microbial production pathways. Depending on the project, the focus may include:
In previous enzyme engineering projects, redox enzyme variants demonstrated increased product conversion and selectivity, together with reduced side-product formation. Hydrolytic enzyme variants showed improvements in activity and stability. These results illustrate how structure-informed enzyme optimisation can contribute to microbial production systems.
Innophore can support projects involving:
The workflow generates prioritised enzyme designs for experimental evaluation. Final strain and enzyme performance should be confirmed through biochemical, fermentation-based, and process-relevant assays.
Innophore GmbH is a biotechnology company that provides a platform for enzyme and drug discovery through its proprietary Catalophore technology. Founded in 2017 in Graz, Austria, the company uses artificial intelligence and 3D point-cloud analysis to characterize protein binding sites rather than focusing on proteins alone. This methodology allows the company to conduct cavity-based searches across entire proteomes, offering capabilities that exceed traditional sequence or fold comparison methods. By transforming molecular structure into actionable data, Innophore supports research and development pipelines by identifying and optimizing protein candidates for applications in biotechnology, pharmaceuticals, and industrial processes.
The company's technology is utilized by global partners in sectors including healthcare, chemicals, and consumer products to accelerate R&D and improve safety. Innophore’s solutions enable clients to detect potential off-target interactions, reduce side effects, and optimize therapeutic or industrial enzymes more efficiently. The company gained significant industry recognition during the COVID-19 pandemic by rapidly identifying the SARS-CoV-2 main protease as a drug target. Innophore maintains collaborations with major technology partners, such as NVIDIA, to leverage advanced computational platforms like BioNeMo for large-scale structural modeling and drug discovery predictions, helping clients bring products to market with greater speed and precision.